Is Ranbaxy Inching Closer To Resolution Of Its GMP Disputes With U.S. FDA?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After more than two years of serious deliberations, Ranbaxy seems to be finally moving forward to resolve charges of significant manufacturing lapses leveled by U.S. FDA at two of its India-based sites